Idorsia
Generated by GPT-5-miniExpansion Funnel Raw 1 → Dedup 0 → NER 0 → Enqueued 0
| Idorsia | |
|---|---|
| Name | Idorsia |
| Type | Public |
| Industry | Pharmaceuticals |
| Founded | 2017 |
| Founder | Jean-Paul Clozel |
| Headquarters | Allschwil, Switzerland |
| Key people | Jean-Paul Clozel, Martine Clozel, David Broich |
| Products | Daridorexant, clazosentan (investigational) |
| Revenue | (2023) CHF (reported) |
| Employees | (2023) ~1,600 |
| Website | idorsia.com |
Idorsia Idorsia is a Swiss biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule therapeutics for central nervous system and cardiovascular disorders. Headquartered in Allschwil, the company was formed from the research assets of a predecessor biotechnology firm and rapidly moved toward clinical development, regulatory submissions, and partnerships across Europe, North America, and Asia. Its strategic emphasis combines in-house medicinal chemistry, translational science, and commercial operations to advance candidate drugs through regulatory pathways such as the European Medicines Agency and the U.S. Food and Drug Administration.
History
Idorsia emerged in the wake of corporate restructuring tied to a prominent Swiss biotech spin-off and transfer of assets from a Basel-based pharmaceutical company. The founders had prior roles at companies tied to the Swiss life sciences cluster, including organizations associated with Jean-Paul Clozel and Martine Clozel, and interactions with institutions like the University of Basel, the Friedrich Miescher Institute, and private equity firms that support biotech. Early milestones included licensing discussions with multinational companies such as Johnson & Johnson, Roche, and Novartis, and engagements with regulatory bodies including the European Medicines Agency and the U.S. Food and Drug Administration. Subsequent corporate events involved public offerings on Swiss financial markets, appointments of executives with experience at GlaxoSmithKline, Pfizer, AstraZeneca, and Amgen, and collaborations with contract research organizations such as Charles River Laboratories and Covance. Strategic choices in this period were influenced by precedent set by companies like Actelion, Roche Pharma Research, and Novartis Institutes for BioMedical Research.
Corporate structure and governance
The company adopted a governance framework featuring a board of directors with members recruited from pharmaceutical and finance sectors, some with backgrounds at companies including Novartis, Roche, UBS, Credit Suisse, and Deloitte. Executive leadership has included individuals who previously served at Pfizer, GlaxoSmithKline, AstraZeneca, Amgen, and Sanofi. Corporate oversight interacts with Swiss regulatory institutions and stock exchange authorities including SIX Swiss Exchange. Auditor and advisory relationships have involved global firms such as KPMG, PwC, and Ernst & Young. Compensation and shareholder relations reference practices common among European biotech peers such as Lonza, Actelion, and Lonza Group. Institutional investors and asset managers with stakes may include BlackRock, Vanguard, and Credit Suisse Asset Management, among others, reflecting capital market engagement seen with biotech companies like Novartis spin-offs and startup financings that involved investors from London, New York, and Zurich.
Research and development
R&D at the company leverages capabilities in medicinal chemistry, preclinical pharmacology, and translational neuroscience, drawing on talent previously associated with Roche Research, Novartis Institutes for BioMedical Research, and academic centers such as ETH Zurich and the University of Geneva. Platforms emphasize orexin receptor biology, endothelin receptor antagonism, and ion channel modulation, aligning with scientific threads explored at institutions like the Scripps Research Institute, Harvard Medical School, and the Karolinska Institutet. Preclinical partnerships have included contract research organizations such as Charles River Laboratories and ICON plc, and translational biomarker work linked to clinics affiliated with University Hospitals like Inselspital Bern and University Hospital Zurich. Clinical development protocols have invoked expertise from clinical research organizations including PRA Health Sciences and Parexel, and regulatory strategy consultations referencing precedent from approvals by the European Medicines Agency, the U.S. Food and Drug Administration, Health Canada, and Japan’s Pharmaceuticals and Medical Devices Agency.
Products and pipeline
The marketed product portfolio and investigational pipeline include small-molecule candidates developed for insomnia, narcolepsy, pulmonary and cerebrovascular indications, and critical care neurology. Clinical-stage programs have progressed through Phase I–III trials that involved investigator sites at academic medical centers such as Massachusetts General Hospital, Charité – Universitätsmedizin Berlin, University College London, and Kyoto University Hospital. Regulatory submissions and label discussions referenced dossiers similar to those filed by competitor therapies from Merck, Eisai, and Johnson & Johnson. Pipeline management and lifecycle planning considered precedents set by companies including Biogen, Eli Lilly, and Bayer in therapeutic areas spanning CNS and cardiovascular disease.
Financial performance
Financial reporting follows Swiss disclosure standards and public filings typical of companies listed on SIX Swiss Exchange, with quarterly and annual results prepared by auditors comparable to Big Four practices. Revenue streams and R&D expenditure patterns mirror those observed at biotech firms during product launch and commercialization phases, and capital allocation decisions were influenced by interactions with investment banks and equity research analysts covering European biotech, including UBS, Credit Suisse, Morgan Stanley, and Goldman Sachs. Cash runway management, licensing income, milestone payments, and commercial sales were reported in financial statements alongside R&D investments and SG&A comparable to peers like Actelion, Lonza, and Galenica.
Partnerships and collaborations
Strategic alliances have involved commercial partnership discussions and licensing negotiations with multinational pharmaceutical companies such as Novartis, Roche, Johnson & Johnson, and Pfizer, as well as collaborations with academic institutions including the University of Basel, ETH Zurich, and Karolinska Institutet. Clinical trial collaborations engaged contract research organizations and academic trial networks like EORTC, Investigator-initiated studies at University Hospital Zurich, and site networks linked to institutions such as Massachusetts General Hospital and Charité – Universitätsmedizin Berlin. Manufacturing and supply chain partnerships invoked relationships with CDMOs and suppliers that include Lonza, Catalent, and Siegfried AG, and business development activities interfaced with investment banks and venture firms from London, New York, and Zurich.